Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.

Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA.

JAMA. 1999 Apr 28;281(16):1520-7.

PMID:
10227322
2.

Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.

MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER.

JAMA. 2000 Jun 7;283(21):2795-801.

PMID:
10838647
3.

Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.

Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, Cuevas I, Carbonero M, Campa HC, Sierra G, Levin M.

Pediatr Infect Dis J. 2001 Nov;20(11):1054-61.

PMID:
11734711
4.

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.

Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Lee SS, Perez JL; 6108A12001 Study Investigators.

Lancet Infect Dis. 2017 Jan;17(1):58-67. doi: 10.1016/S1473-3099(16)30314-0. Epub 2016 Oct 11.

PMID:
27745812
5.

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.

MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM.

JAMA. 1998 Nov 18;280(19):1685-9.

PMID:
9832000
6.

Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.

Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, Gheesling LL, Carlone GM, Ward JI.

JAMA. 1996 May 15;275(19):1499-503.

PMID:
8622225
7.

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.

de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, Gattas VL, Vasconcelos Hde G, et al.

Lancet. 1992 Oct 31;340(8827):1074-8. Erratum in: Lancet 1992 Dec 19-26;340(8834-8835):1554. Gral IM [corrected to Landgraf IM].

PMID:
1357461
8.

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease.

Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, et al.

Vaccine. 1995 Jun;13(9):821-9.

PMID:
7483804
9.

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.

Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, Rosenqvist E, Holst J, Nokleby H, Sotolongo F, Sierra G, Campa HC, Carlone GM, Williams D, Dykes J, Kapczynski D, Tikhomirov E, Wenger JD, Broome CV.

J Infect Dis. 1998 Mar;177(3):683-91.

PMID:
9498448
10.

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.

Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17.

PMID:
25795256
11.

New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.

Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, Mulholland K, Martin D.

Pediatr Infect Dis J. 2007 Apr;26(4):345-50.

PMID:
17414400
12.

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group.

Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Erratum in: Lancet. 2015 May 2;385(9979):1728.

PMID:
22260988
13.

Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine.

Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA.

Vaccine. 2000 May 22;18(23):2476-81.

PMID:
10775781
14.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

15.

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

Noronha CP, Struchiner CJ, Halloran ME.

Int J Epidemiol. 1995 Oct;24(5):1050-7.

PMID:
8557439
16.

Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.

Fischer M, Carlone GM, Holst J, Williams D, Stephens DS, Perkins BA.

Vaccine. 1999 May 14;17(19):2377-83.

PMID:
10392619
17.

Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.

Milagres LG, Ramos SR, Sacchi CT, Melles CE, Vieira VS, Sato H, Brito GS, Moraes JC, Frasch CE.

Infect Immun. 1994 Oct;62(10):4419-24.

18.

Age-related immunogenicity of meningococcal polysaccharide vaccine in aboriginal children and adolescents living in a Northern Manitoba reserve community.

Law BJ, Rosenberg T, MacDonald NE, Ashton FE, Huang JC, King WJ, Ferris WJ, Gray GJ.

Pediatr Infect Dis J. 1998 Oct;17(10):860-4.

PMID:
9802625
19.

Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.

Rosenqvist E, Harthug S, Frøholm LO, Høiby EA, Bøvre K, Zollinger WD.

J Clin Microbiol. 1988 Aug;26(8):1543-8.

20.

Phase II meningococcal B vesicle vaccine trial in New Zealand infants.

Jackson C, Lennon DR, Sotutu VT, Yan J, Stewart JM, Reid S, Crengle S, Oster P, Ypma E, Aaberge I, Mulholland K, Martin DR.

Arch Dis Child. 2009 Oct;94(10):745-51. doi: 10.1136/adc.2007.132571. Epub 2008 Oct 6.

PMID:
18838420

Supplemental Content

Support Center